4D Molecular Therapeutics FDMT Operating Lease Liabilities
Operating Lease Liabilities at other companies
Other financials
Where this comes from
Reported directly by 4D Molecular Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityNoncurrent.
The official record: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about 4D Molecular Therapeutics's operating lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is 4D Molecular Therapeutics's operating lease liabilities?
- 4D Molecular Therapeutics (FDMT) reported operating lease liabilities of $15.05M in Q1 2026.
- How has 4D Molecular Therapeutics's operating lease liabilities changed year-over-year?
- 4D Molecular Therapeutics's operating lease liabilities decreased by 17.2% year-over-year, from $18.17M to $15.05M.
- What is the long-term trend for 4D Molecular Therapeutics's operating lease liabilities?
- Over 5 years (2020 to 2025), 4D Molecular Therapeutics's operating lease liabilities has grown at a -0.3% compound annual growth rate (CAGR), from $16.1M to $15.82M.
- What does operating lease liabilities mean?
- Long-term portion of operating lease obligations extending beyond one year, representing committed future rent payments.